-
Parkinson's new drug! Sumitomo pharmaceutical's new apomorphine sublingual membrane agent apl-130277 has entered the review in the United States, rapidly treating various off events on demand
Time of Update: 2019-12-28
December 27, 2019 / Biovalley bio on / -- Sumitomo Pharma, a US subsidiary of Sumitomo pharmaceutical, recently announced that the US Food and Drug Administration (FDA) has
-
Parkinson's new drug! Kirin nourianz (Istra defylline) is listed in the United States for treatment of off events
Time of Update: 2019-10-16
As an additional treatment of levodopa / carbidopa, it is used for adult patients with Parkinson's disease (PD) who are experiencing the "off" event.
-
[Yao Kejun] drug review trends: new drugs and rare disease drugs urgently needed in clinical practice are accepted; Parkinson's disease innovative therapy is listed in the United States; Xiehe Kirin, Bayer, Hengrui, Renfu
Time of Update: 2019-09-02
In response to the urgent needs of patients for new drug-resistant antibiotics, in September 2003, the U.S. FDA approved for the first time the use of daptomycin for injection (trade name: Cubicin ®) through the priority approval process.
-
Good news for Chinese Parkinson patients! Youshibi neupro (rotigotine patch) approved by China
Time of Update: 2018-07-05
With the approval of neupro in China, we are happy to bring this drug to millions of Parkinson's patients, and provide them with a convenient treatment plan to help them manage their condition.
-
Another new Parkinson's disease drug approved by FDA
Time of Update: 2017-08-28
Source: the US FDA approved the new drug gocovri (amantadine, amantadine, formerly ads-5102) sustained-release capsule of adamas pharmaceuticals for the treatment of movement disorders in Parkinson's disease patients receiving levodopa treatment recently.
-
In half a year, heavy new drugs appear frequently, and nervous system diseases are frequently used
Time of Update: 2017-08-14
With the deepening of social aging, the incidence rate of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease is also increasing
The market
-
Tianbian Mitsubishi's $1.1 billion acquisition of neuroderm as Parkinson's potential drug
Time of Update: 2017-07-25
Source: Sina Pharmaceutical News on July 25, 2017, Mitsubishi Tanabe Pharma, a Japanese pharmaceutical company, recently announced that it had signed a $1.1 billion acquisition
-
FDA approved the first new Parkinson's disease drug in ten years
Time of Update: 2017-03-22
FDA announced that xadago (safinamide), a new Parkinson's disease drug developed by newron pharmaceuticals, has been approved for marketing as an additional therapy in addition to levodopa / carbidopa treatment.
-
Boost enterprise confidence adjustment of export tax rebate rate of pharmaceutical products
Time of Update: 2015-02-03
The varieties of the tax rebate rate adjustment have the characteristics of high added value, international competitiveness and low energy consumption, which play a leading role in export orientation and boost the confidence of pharmaceutical enterprises in foreign trade.
-
CDE drug review weekly report (2015.1.19-1.25
Time of Update: 2015-01-26
For hydromorphone hydrochloride sustained-release tablets, there is no listing, only two enterprises apply, namely Johnson & Johnson and Qinghai pharmaceutical factory.
